Subscribe To
Oral health ingredient market is anticipated to reach us$ 10.36 billion by 2033: fact.mr report
High adoption of oral care products to address various issues such as gum health problems and tooth sensitivit...
October 23, 2023, 9:00 pm
Pcy: way too risky now and better options anyway
Invesco Emerging Markets Sovereign Debt ETF is a high-risk investment due to its exposure to non-investment grade bonds and ...
October 23, 2023, 5:38 pm
Cytomx therapeutics presents preclinical profile of epcam-directed antibody drug conjugate cx-2051 at 2023 world adc conference
– CX-2051 is tailored for treatment of EpCAM-expressing cancers by matching target expression and tumor sens...
October 18, 2023, 8:30 pm
Xrp news: fake news frenzy sends xrp to $0.51 – what’s next?
XRP’s Monday rally to $0.51 showcased the crypto market’s sensitivity to SEC’s ETF decisions. The...
October 17, 2023, 2:40 am
Carmot therapeutics highlights clinical data from its pipeline of treatments for obesity and diabetes at obesityweek®
– CT-388 administered once-weekly resulted in clinically meaningful weight loss and insulin sensitivity...
October 15, 2023, 4:00 pm
Garrett motion: electric vehicles are just the next chapter
Garrett Motion is a leading automotive technology company specializing in turbocharging and electric boosting solutions. Although they play an importa...
October 11, 2023, 9:16 pm
Clearway energy: a historical near-8% yield from clean energy
Clean energy investors have experienced significant capital loss in the past four months, driven by NextEra Energy Partners' cut in growth guidance. C...
October 10, 2023, 12:33 pm
Jpmorgan chase: stretching out its lead in a tough bank stock environment
JPMorgan Chase has handily outperformed its peers in the banking sector, with 10% to 30% outperformance on a year-to-date basis on the back of much st...
October 9, 2023, 12:13 pm
Cintas: shares dressed for success, remain expensive amid a powerful uptrend
Small and mid-sized companies in the industrials sector outperform tech-related sectors in 2023. Cintas is the leading provider of corporate uniform r...
October 9, 2023, 2:23 am
British american tobacco: ray dalio's wisdom on passive income
In Ray Dalio's mind (and ours too), diversification among different stocks is only one step - not the only one and not even the first one. Diversifica...
October 3, 2023, 2:28 am
Cqqq: compelling on the surface but fraught with longer-term risks
Invesco China Technology ETF offers exposure to the Chinese tech industry, but has underperformed compared to KraneShares CSI China Internet ETF. CQQQ...
October 1, 2023, 6:09 am
The week ahead: global currencies brace for impactful economic data releases
his week poses high sensitivity for major currencies like the Dollar, Euro, and Pound as investors watc...
October 1, 2023, 2:00 am
Here's why gordon haskett downgraded macy's
Chuck Grom, Gordon Haskett analyst, joins 'Squawk on the Street' to discuss why he downgraded Macy's stock, the ...
September 27, 2023, 12:13 pm
Viatris and ocuphire pharma get fda green light for eye treatment
Viatris Inc. VTRS, and Ocuphire Pharma Inc. OCUP, +3.08% said Wednesday that the U.S. Food and Drug Administration has approved Ryzumvi to treat the s...
September 27, 2023, 8:21 am
Mainz biomed to present detailed results of colofuture study at international conference on gastroenterology
Clinical trial evaluating the Company's novel mRNA biomarkers demonstrated sensitivity for colorectal c...
September 27, 2023, 8:01 am
Stocks are at risk as rates market gets everyone to sit up - bofa
BofA says that it sure looks like markets are starting to sit up as the gap between the optimistic scenario priced in by equities and the much uglier ...
September 26, 2023, 10:37 am
Manulife: taking a closer look at canadian life insurance
Since 2018, Manulife has been successfully implementing its strategic plan to de-risk its portfolio. Manulife offers a strong dividend yield, attracti...
September 25, 2023, 6:29 pm
Acrivon therapeutics to highlight its acr-368 oncosignature test, used in ongoing phase 2 study to treat patients based on predicted sensitivity to monotherapy with its chk1/2 inhibitor acr-368, at th
WATERTOWN, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) — Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clini...
September 19, 2023, 8:32 pm
Bsjo: decreasing risk, increasing rewards as time passes
The Invesco BulletShares 2024 High Yield Corporate Bond ETF is a fixed-income ETF with a termination date of December 15, 2024. The majority of the fu...
September 19, 2023, 10:47 am
Pacific biosciences: looks appealing in the fast-growing long-read sequencing market
Pacific Biosciences has a leading position within the fast-growing long-read DNA sequencer market. Moreover, it is expanding its high-accuracy long-re...
September 10, 2023, 3:52 am